[Is the PCA3 cost-effective in Latin America and the Caribbean?]

Salud Publica Mex. 2018 Jan-Feb;60(1):104-105. doi: 10.21149/8718.
[Article in Spanish]
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / economics
  • Antigens, Neoplasm / blood*
  • Biomarkers, Tumor / blood*
  • Caribbean Region
  • Cost-Benefit Analysis
  • Developing Countries / economics
  • Early Detection of Cancer / economics*
  • Humans
  • Latin America
  • Male
  • Neoplasm Proteins / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / economics
  • Sensitivity and Specificity

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Neoplasm Proteins
  • prostate cancer antigen 3, human